Use of prostate-specific antigen in the follow-up of patients with localized prostate cancer: Results of a nationwide survey of urologists

Urology

Volumn 68, Issue 1, 2006, Pages 80-84

  Penson, David ^a   Moul, Judd ^b   Gandhi, Sanjay ^c   Newling, Don ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b DUKE UNIVERSITY   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HEALTH CARE ORGANIZATION; HUMAN; INTERVIEW; MALE; MEDICAL DECISION MAKING; MEDICAL INFORMATION; MEDICAL PRACTICE; MEDICAL RESEARCH; PHYSICIAN; PRIORITY JOURNAL; PROSTATE CANCER; RANDOM SAMPLE; RECURRENT CANCER; TREATMENT INDICATION;

DATA COLLECTION; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; UROLOGY;

EID: 33745865560     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.01.028     Document Type: Article

References (18)

1. Partin A.W., Hanks G.E., Klein E.A., et al. Prostate-specific antigen as a marker of disease activity in prostate cancer. Oncology (Huntingt) 16 (2002) 1218-1224
2. Zeliadt S.B., Potosky A.L., Etzioni R., et al. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer. SEER-Medicare trends 1991 to 1999. Urology 64 (2004) 1171-1176
3. Moul J.W., Wu H., Sun L., et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 171 (2004) 1141-1147
4. Moul J.W. Prostate specific antigen only progression of prostate cancer. J Urol 163 (2000) 1632-1642
5. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
6. Baker S.G., and Kramer B.S. A perfect correlate does not a surrogate make. BMC Med Res Methodol 3 (2003) 16
7. U.S. Food and Drug Administration: http://www.fda.gov/cder/drug/cancer_endpoints/ProstatePresent/Carroll_files/frame.htm, 2004. Accessed May 12, 2006.
8. Johnstone P.A., Booth R., Riffenburgh R.H., et al. Initiation of salvage therapy for prostate cancer. Prostate Cancer Prostatic Dis 5 (2002) 136-143
9. Albertsen P.C., Hanley J.A., Penson D.F., et al. Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. J Urol 171 (2004) 2221-2225
10. Patel A., Dorey F., Franklin J., et al. Recurrence patterns after radical retropubic prostatectomy. clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 158 (1997) 1441-1445
11. Leibman B.D., Dillioglugil O., Scardino P.T., et al. Prostate-specific antigen doubling times are similar in patients with recurrence after radical prostatectomy or radiotherapy. a novel analysis. J Clin Oncol 16 (1998) 2267-2271
12. Roberts S.G., Blute M.L., Bergstralh E.J., et al. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 76 (2001) 576-581
13. D'Amico A.V., Moul J.W., Carroll P.R., et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95 (2003) 1376-1383
14. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement. guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
15. Etzioni R., Berry K.M., Legler J.M., et al. Prostate-specific antigen testing in black and white men. an analysis of Medicare claims from 1991-1998. Urology 59 (2002) 251-255
16. Klotz L.H. PSAdynia and other PSA-related syndromes. a new epidemic-a case history and taxonomy. Urology 50 (1997) 831-832
17. Lofters A., Juffs H.G., Pond G.R., et al. "PSA-itis". knowledge of serum prostate specific antigen and other causes of anxiety in men with metastatic prostate cancer. J Urol 168 (2002) 2516-2520
18. Sartor C.I., Strawderman M.H., Lin X.H., et al. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys 38 (1997) 941-947